CRISPR specialist raises $80m in funding

US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

CRISPR tech market to reach $1.72m by 2023: report

23 November 2018 The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.

Americas

Allergan to pay Editas $90m for development of CRISPR eye treatment

20 March 2017 Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.

Europe

Are the Broad Institute’s CRISPR patents too broad?

29 October 2015 Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.

More on this story

Biotechnology

CRISPR tech market to reach $1.72m by 2023: report

23 November 2018 The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.

Americas

Allergan to pay Editas $90m for development of CRISPR eye treatment

20 March 2017 Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.

Europe

Are the Broad Institute’s CRISPR patents too broad?

More on this story

Biotechnology

CRISPR tech market to reach $1.72m by 2023: report

23 November 2018 The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.

Americas

Allergan to pay Editas $90m for development of CRISPR eye treatment

20 March 2017 Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.

Europe

Are the Broad Institute’s CRISPR patents too broad?